An observational study in Inherited Retinal Dystrophies, Retinitis Pigmentosa (RP) and Stargardt Disease, sponsored by Fondazione G.B. Bietti, IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fondazione G.B. Bietti, IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Retinitis Pigmentosa with a site in Italy — 4 open to participants now, 7 under way, 1 of them phase 3. Retinitis Pigmentosa · Italy.
Among the 15 studies in Retinitis Pigmentosa with a site in Italy, this one is the only one that started in 2025, is one of 6 observational ones, and was the 15th registered.
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
Browse Retinitis Pigmentosa studies →4 of the 15 studies in Retinitis Pigmentosa with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Jaeb Center for Health Research · Sites in Italy, United States, Australia and 11 more countries
Ages 4+
IRCCS San Raffaele · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 3
First in 2011; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 18 is below the median of 52 across 89 observational studies indexed under Retinitis Pigmentosa.
Median enrollment 48 across the 8 interventional studies, 86 across the 6 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
Fondazione G.B. Bietti, IRCCS is the lead sponsor of 21 studies on the registry; 8 are open to participants now.
Fondazione G.B. Bietti, IRCCS has 1 study filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Retinitis Pigmentosa with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study aims to perform a detailed morpho-anatomical and electro-functional characterization of patients affected by IRD, to investigate on the features of specific retinal layers (outer and inner) and to identify the functional involvement of macular elements located in specific areas. Through a systematic approach to anatomical and functional pattern classifications, this study seeks to refine the phenotypic understanding of IRD and to contribute to a deeper comprehension of its pathophysiological underpinnings, for exploring whether subretinal factors are involving in the etiopathogenesis.
This single-center retrospective observational study evaluates retinal structure and function in patients with clinically confirmed inherited retinal dystrophies. Patients are identified consecutively from those evaluated between 2015 and August 31, 2025. After written informed consent is obtained, demographic and clinical data are extracted from existing records, together with results from a single previously completed ophthalmic visit (Visit 1). The data include medical history, best-corrected visual acuity, anterior and posterior segment examination, intraocular pressure, spectral-domain optical coherence tomography, optical coherence tomography angiography, multifocal electroretinography, multifocal photopic negative response recordings, visual field testing, and documented ocular complications related to inherited retinal dystrophies.
Patients aged 18 to 90 years with clinically confirmed inherited retinal dystrophies who were evaluated at the study center between 2015 and August 31, 2025, and have the clinical and instrumental records required by the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with clinically confirmed inherited retinal dystrophies identified consecutively from those evaluated at the study center between 2015 and August 31, 2025
Central Retinal Thickness Measured by SD-OCT
Central retinal thickness, in micrometers (µm), measured by spectral-domain optical coherence tomography (SD-OCT).
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Ring 1 Response Amplitude Density Measured by Multifocal Electroretinography
Response amplitude density, in nV/deg², measured by multifocal electroretinography (mfERG) in the innermost fovea-centered ring (R1).
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Best-Corrected Visual Acuity
Mean best-corrected visual acuity, expressed in logMAR.
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Multifocal Electroretinography Response Amplitude Density by Macular Ring
Response amplitude density, in nV/deg², measured by multifocal electroretinography (mfERG) and reported separately for the five fovea-centered rings (R1-R5).
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Multifocal Photopic Negative Response Amplitude Density by Macular Ring
Response amplitude density, in nV/deg², measured from multifocal photopic negative response (mfPhNR) recordings and reported separately for the five fovea-centered rings (R1-R5).
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Mean Perimetric Sensitivity
Mean perimetric sensitivity derived from visual field testing.
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Inner and Outer Retinal Layer Thickness by Macular Region
Thickness of the inner and outer retinal layers, in micrometers (µm), measured by SD-OCT in localized macular regions defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) map.
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Macular Vessel Density Measured by OCT Angiography
Vessel density measured by optical coherence tomography angiography (OCT-A) in localized macular regions and reported separately for the superficial capillary plexus, deep capillary plexus, and choriocapillaris.
Time frame: At a single previously completed ophthalmic visit (Visit 1).
Inherited Retinal Dystrophy-Related Ocular Complications
Ocular complications documented in patients with inherited retinal dystrophies, including macular edema and cataract.
Time frame: At a single previously completed ophthalmic visit (Visit 1).
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — The individual participant data (IPD) that will be eventually shared are retinal morpho-functional evaluation of patients affected by inherited retinal dystrophies (OCT; OCT-A, mfERG, mfPhNR data), visual field, visual acuity, ocular complications related to IRDs.
Ran from Dec 2025 to primary completion in Dec 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione G.B. Bietti, IRCCS